1206124-34-6

Basic information

• Product Name: (R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate
• Synonyms: (R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate
• CAS NO: 1206124-34-6
• Molecular Weight: 485.546
• Mol File: 1206124-34-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate(1206124-34-6)
• EPA Substance Registry System: (R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate(1206124-34-6)

Safety Data

• Hazardous Substances Data: 1206124-34-6(Hazardous Substances Data)

Usage

General Description

(R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate is a complex organic compound with a long chemical name. It is an ester, meaning it is derived from an acid and an alcohol, specifically ethyl acetate. The compound also contains a tetrahydrocyclopenta[b]indol structure with a cyclopentyl and trifluoromethyl benzyl group attached. (R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate is likely to have pharmaceutical or medicinal applications due to its complex structure and diverse functional groups. Further research and testing would be needed to fully understand the properties and potential uses of this chemical.

Upstream product

• 191348-14-8 2-iodo-4-methoxylaniline 
• 1737-36-6 4-chloro-3-(trifluoromethyl)benzoic acid 
• 1318262-62-2 ethyl 2-(7-(benzyloxy)-1,2-dihydrocyclopenta[b]indol-3(4H)-ylidene)acetate 
• 380350-42-5 ethyl 2-(2-morpholinocyclopent-2-enylidene)acetate 
• 161622-16-8 methyl 4-cyclopentyl-3-(trifluoromethyl)benzoate 
• 1206124-14-2 ethyl 2-(7-methoxy-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate 
• 1206125-18-9 4-cyclopentyl-3-(trifluoromethyl)benzaldehyde 
• 1206125-16-7 4-bromo-1-cyclopentyl-2-(trifluoromethyl)benzene 
• 1206125-14-5 1-cyclopentyl-2-(trifluoromethyl)benzene 
• 1206125-13-4 1-(2-(trifluoromethyl)phenyl)cyclopentanol 
• 41301-66-0 ethyl 1-(2-ethoxy-2-oxoethyl)-2-oxocyclopentanecarboxylate 
• 957205-39-9 (4-cyclopentyl-3-(trifluoromethyl)phenyl)methanol 
• 104115-44-8 (2-oxocyclopent)acetic acid 
• 20826-94-2 ethyl (2-oxocyclopentyl)acetate 

Downstream Products

• 1206123-55-8 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid 
• 1206123-37-6 [(3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 1206123-97-8 (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, L-arginine salt 

Relevant articles and documents

COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain compounds of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor: Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, an inflammatory skin disease or disorder, cancer, psoriasis, atopic dermatitis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, and acne, microbial infections or diseases and viral infections or diseases.

PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF

The present invention relates to processes and intermediates useful in the preparation of of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).